Inhibikase Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $287.17M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | During market hours | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | During market hours | – | $-0.10 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | During market hours | – | $-0.13 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | During market hours | – | $-0.11 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | During market hours | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 17, 2022 | During market hours | $7.29K | $-0.18 | – |
| Q1 FY2021 Ended Mar 31, 2021 | Apr 1, 2021 | Before market open | – | – | – |
Press releases
Announcements Inhibikase Therapeutics filed with the SEC
Inhibikase Therapeutics Announces Second Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Inhibikase Therapeutics Announces FDA Orphan Drug Designation
Regulation FD disclosure · EX-99.1 to Form 8-K
of $50 Million of Shares Through its At-the-Market (ATM)
Other events · EX-99.1 to Form 8-K
Inhibikase Therapeutics Announces First Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Inhibikase Therapeutics Announces Enrollment of
Regulation FD disclosure · EX-99.1 to Form 8-K
Inhibikase Therapeutics Announces Full Year 2025
Results of operations · EX-99.1 to Form 8-K
Disclaimer This presentation contains information that may constitute
Other events · EX-99.1 to Form 8-K
Inhibikase Therapeutics Announces Third Quarter
Results of operations · EX-99.1 to Form 8-K
Inhibikase Therapeutics Announces Second Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Overview August 2025 Exhibit
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Inhibikase Therapeutics Announces First Quarter
Results of operations · EX-99.1 to Form 8-K
Agreement is made and entered into as of April 11, 2025 (the Effective Date ) by and between Garth Lees-Rolfe ( Consultant ) and Inhibikase Therapeutics, Inc. (with its successors and assigns, the
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
This Employment Agreement (Agreement) is made between Inhibikase Therapeutics, Inc . (the Company), and David
Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Inhibikase Therapeutics Announces Appointment of David McIntyre
Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
Results of operations · EX-99.1 to Form 8-K
Inhibikase Announces Expansion of Senior Leadership Team
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Companys Growth
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Disease-Modifying Therapeutics for Pulmonary Arterial Hypertension Inhibikase.com : IKT
Regulation FD disclosure · EX-99.1 to Form 8-K
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Disease-Modifying Therapeutics for Neurodegenerative Disease, Cancer and Cardiopulmonary Disease Inhibikase.com : IKT
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Regulation FD disclosure · EX-99.1 to Form 8-K
Inhibikase Therapeutics Announces Preliminary Outcomes of its
Other events · EX-99.1 to Form 8-K
Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity
Regulation FD disclosure · EX-99.1 to Form 8-K
By electronic delivery to: [email protected]; [email protected]
Other events · EX-99.1 to Form 8-K
Inhibikase Therapeutics Regains Compliance with
Other events · EX-99.2 to Form 8-K
June 29, 2023 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Transforming fundamental and clinical research in neurodegenerative disease Inhibikase.com : IKT
Regulation FD disclosure · EX-99.1 to Form 8-K
Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering
Material agreement · Agreement terminated · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on
Other events · EX-99.1 to Form 8-K
Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic
Other events · EX-99.2 to Form 8-K
Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period
Results of operations · EX-99.1 to Form 8-K
FDA Clinical Hold on IkT-148009 Programs
Other events · EX-99.1 to Form 8-K
IkT-148009 As A Potential Disease-Modifying Therapy in Parkinson’s Disease Poster 789 Werner MH,1,7 Karuppagounder SS,2,3 Rush R,1
Regulation FD disclosure · EX-99.1 to Form 8-K
Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Disease-Modifying Therapeutics for Neurodegenerative Disease & Cancer Inhibikase.com : IKT
Regulation FD disclosure · EX-99.1 to Form 8-K
Modifying Therapeutics for Parkinson’s and Related Disorders 2Q 2022 BUSINESS PRESENTATION IKT Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Abl-kinase Inhibition AD-PD 2022, March 18 2022
Regulation FD disclosure · EX-99.1 to Form 8-K